Trial Profile
The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2019
Price :
$35
*
At a glance
- Drugs Metformin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Sanofi
- 10 Nov 2019 Status changed from recruiting to discontinued.
- 31 Jan 2007 New trial record.